| Rebif (human IFN-β-1a) / EMD Serono |
PROOF, NCT00599274: Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis |
|
|
| Completed | N/A | 136 | US, Canada, Europe, RoW | Interferon beta-1a, Avonex, Rebif | Biogen | Multiple Sclerosis | | 05/03 | | |
NCT01142557: An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis |
|
|
| Completed | N/A | 522 | Europe | Interferon beta-1a (Rebif), Rebif | Merck KGaA, Darmstadt, Germany, Gesellschaft für Therapieforschung mbH | Multiple Sclerosis | 11/05 | 11/05 | | |
| Completed | N/A | 36 | US | | EMD Serono, Pfizer | Multiple Sclerosis | 10/07 | 02/08 | | |
NCT00137176: EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis |
|
|
| Completed | N/A | 30 | US | Rebif | University of North Carolina, Chapel Hill | Multiple Sclerosis | 10/07 | 10/08 | | |
NCT01142453: An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients |
|
|
| Completed | N/A | 231 | Europe | Interferon beta 1a, Rebif | Merck KGaA, Darmstadt, Germany, Gesellschaft für Therapieforschung mbH | Relapsing-Remitting Multiple Sclerosis | 06/08 | 06/08 | | |
TOURIMS, NCT01142492: A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®) |
|
|
| Completed | N/A | 403 | Europe | Interferon beta-1a, Rebif | Merck KGaA, Darmstadt, Germany | Relapsing-Remitting Multiple Sclerosis | 07/08 | 07/08 | | |
RETURN, NCT01142518: An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone |
|
|
| Completed | N/A | 86 | Europe | Interferon beta 1a, Rebif® | Merck KGaA, Darmstadt, Germany | Relapsing-Remitting Multiple Sclerosis | 03/09 | 03/09 | | |
| Completed | N/A | 290 | Europe | | Merck KGaA, Darmstadt, Germany | Multiple Sclerosis | 11/10 | 01/11 | | |
AIMS, NCT01080573: Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis |
|
|
| Completed | N/A | 1257 | Europe | | Merck KGaA, Darmstadt, Germany | Multiple Sclerosis | 04/11 | 04/11 | | |
COMPARE, NCT01141751: An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy |
|
|
| Completed | N/A | 334 | Canada | | Merck KGaA, Darmstadt, Germany | Multiple Sclerosis, Relapsing-Remitting | 06/11 | 06/11 | | |
|
STAR, NCT01080027: Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings |
|
|
| Completed | N/A | 254 | Europe | Rebif® New Formulation, Interferon beta1-A | Merck KGaA, Darmstadt, Germany, Merck A.E., Greece, Merck OY, Finland, Merck B.V., Netherlands, Merck A.B., Sweden, Merck, S.A., Portugal | Multiple Sclerosis, Relapsing Remitting | 06/11 | 06/11 | | |
Leptin, NCT01067573: The Role of Serum Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment |
|
|
| Completed | N/A | 20 | US | | University of South Florida, EMD Serono | Multiple Sclerosis | | 07/11 | | |
REPLAY, NCT01207648: Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects |
|
|
| Completed | N/A | 307 | US, Canada, Europe, RoW | Rebif® | EMD Serono | Multiple Sclerosis | 07/11 | 07/11 | | |
NCT00914758: Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS) |
|
|
| Unknown status | N/A | 1 | US | | Washington Neuropsychology Research Group, Genzyme, a Sanofi Company | Relapsing Remitting Multiple Sclerosis | 10/11 | 12/11 | | |
NCT01074346: Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis |
|
|
| Completed | N/A | 60 | RoW | Interferon-β-1a, Rebif® | Merck KGaA, Darmstadt, Germany | Multiple Sclerosis | 11/11 | 11/11 | | |
SCANSMART, NCT01125475: A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects |
|
|
| Completed | N/A | 61 | Europe | RebiSmart | Merck KGaA, Darmstadt, Germany, Merck Serono Norway, Smerud Medical Research International AS | Relapsing Remitting Multiple Sclerosis (RRMS) | 03/12 | | | |
|
NCT00391352: fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls |
|
|
| Completed | N/A | 21 | US | IFN-β-1a (Rebif®) | Waukesha Memorial Hospital, The Cleveland Clinic | Relapsing-Remitting Multiple Sclerosis | 08/12 | 08/12 | | |
NCT01112345: An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters |
|
|
| Completed | N/A | 133 | Europe | | Merck KGaA, Darmstadt, Germany, Merck A.E., Greece | Multiple Sclerosis, Relapsing-Remitting | 09/12 | 09/12 | | |
READER, NCT01601080: An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device |
|
|
| Completed | N/A | 230 | Europe | | Merck KGaA, Darmstadt, Germany, Merck Serono Limited, UK | Relapsing Multiple Sclerosis | 10/12 | | | |
| Completed | N/A | 2878 | US | Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b, Copaxone®, Avonex®, Rebif®, Betaseron® | Teva Neuroscience, Inc. | Multiple Sclerosis | 12/12 | 01/13 | | |
|
|
|
|
|
|
|
|
SMART, NCT01108887: An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™. |
|
|
| Completed | N/A | 912 | Europe | | Merck KGaA, Darmstadt, Germany, Merck Serono S.A., Geneva | Multiple Sclerosis, Relapsing-Remitting | 01/13 | 01/13 | | |
|
|
ReNew, NCT01101776: Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. |
|
|
| Completed | N/A | 49 | RoW | Interferon beta-1a (Rebif), Rebif New Formulation | Merck KGaA, Darmstadt, Germany, Merck Serono Australia Pty Ltd | Multiple Sclerosis | 04/13 | 04/13 | | |
SKORE, NCT01075880: Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® |
|
|
| Completed | N/A | 300 | Europe | Rebif (Interferon beta-1a), Rebif | Merck KGaA, Darmstadt, Germany, Merck spol.s.r.o., Czech Republic | Multiple Sclerosis, Relapsing-Remitting | 06/13 | 06/13 | | |
MusiClock, NCT01110993: An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF) |
|
|
| Completed | N/A | 65 | Europe | | Merck KGaA, Darmstadt, Germany | Multiple Sclerosis, Relapsing-Remitting | 09/13 | 09/13 | | |
| Completed | N/A | 198 | Canada | RebiSmart™, Rebif | Merck KGaA, Darmstadt, Germany, EMD Inc., Canada | Multiple Sclerosis, MS | 04/14 | 04/14 | | |
|
|
EMR200136_550, NCT01601119: Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients |
|
|
| Completed | N/A | 545 | Europe | Rebif, Other: Disease modifying therapies (DMT) | Merck KGaA, Darmstadt, Germany, Merck Serono Limited, UK | Relapsing Multiple Sclerosis | 07/14 | 07/14 | | |
| Terminated | N/A | 306 | US | Standard Services of Group A (Group A1), Customized Services of Group A (Group A2), Group B | EMD Serono | Multiple Sclerosis, Relapsing-Remitting | 01/15 | 01/15 | | |
| Completed | N/A | 296 | Canada | MACFIMS, MSQoL-54 | Centre hospitalier de l'Université de Montréal (CHUM), EMD Serono Canada Inc. | Multiple Sclerosis | 05/15 | 12/16 | | |
ADHERQOL, NCT02394782: Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis |
|
|
| Terminated | N/A | 8 | Europe | RebiSmart®2.0, MSdialog™ | Merck KGaA, Darmstadt, Germany | Multiple Sclerosis, Relapsing-remitting | 11/15 | 03/16 | | |
NCT02419638: Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS |
|
|
| Withdrawn | N/A | 0 | US | Rebif (IFN β-1a subcutaneous three times per week), Tecifdera (dimethyl fumarate) | Brigham and Women's Hospital, EMD Serono | Multiple Sclerosis | 12/15 | 02/16 | | |
PROTRACT, NCT02823951: Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif® |
|
|
| Completed | N/A | 479 | US, Canada | Rebif, Tecfidera | IMS HEALTH GmbH & Co. OHG, EMD Serono | Relapsing-remitting Multiple Sclerosis | 04/17 | 02/18 | | |
MESTRE-MS, NCT02949908: MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS) |
|
|
| Terminated | N/A | 2 | Europe | Rebif, IFNβ-1b | Merck KGaA, Darmstadt, Germany, Merck B.V., Netherlands | Multiple Sclerosis | 08/17 | 08/17 | | |
| Completed | N/A | 34 | US | | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Relapsing-Remitting Multiple Sclerosis | 05/18 | 05/18 | | |
| Completed | N/A | 2089 | Europe | Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG, Extavia (interferon beta-1b), Novartis Pharma AG, Rebif (interferon beta-1a), Merck Serono Europe Ltd, Plegridy (peginterferon beta-1a), Biogen Idec Ltd, Avonex (interferon beta-1a), Biogen Idec Ltd, MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046), No MSDMDs therapy (control) | Bayer, EPID Research, Biogen, Merck Serono Europe Ltd, Novartis Pharmaceuticals | Multiple Sclerosis | 08/18 | 08/18 | | |
PERFECT, NCT03347370: A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis |
|
|
| Completed | N/A | 626 | Europe | SC Peginterferon beta-1a, Plegridy, SC interferon beta-1a, Rebif, SC interferon beta-1b, Betaferon, Extavia | Biogen, AMS Advanced Medical Services GmbH | Multiple Sclerosis, Relapsing-Remitting | 07/19 | 07/19 | | |
| Completed | N/A | 594 | Europe, RoW | Rebif (Interferon beta-1a) | Merck KGaA, Darmstadt, Germany, Merck Serono Middle East FZ LLC | Relapsing Multiple Sclerosis (RMS) | 07/20 | 07/20 | | |
| Recruiting | N/A | 900 | US | Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy, Tysabri, Lemtrada, Ocrevus, Rituxan, Mavenclad, Kesimpta, Briumvi, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso | Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society | Multiple Sclerosis, Relapsing-Remitting | 08/25 | 08/25 | | |
INFORM, NCT06053749: An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden |
|
|
| Not yet recruiting | N/A | 100 | Europe | Avonex (IFNβ-1-a, Biogen Netherlands B.V), Rebif (IFNβ-1-a, Merck Europe B.V.), Extavia (IFNβ-1-b, Novartis Europharm Limited), Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG), Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V), MS disease modifying drugs (MSDMDs) | Bayer, Biogen Netherlands B.V, Novartis Europharm Limited, Merck Europe B.V. | Multiple Sclerosis (MS) | 03/26 | 03/26 | | |
